Is Bio-Techne Corporation (TECH) Overvalued?
We dive into why Bio-Techne Corporation (TECH) could be considered overvalued on 2026-07-23, based on AAII’s Value Score and Grade.Michael Rose
| SECTOR | INDUSTRY |
| Health Care | Life Sciences Tools & Services |
A+ Stock Grade Summary:
| VALUE: |
|
|
| GROWTH: |
|
|
| MOMENTUM: |
|
|
| EPS REVISIONS: |
|
|
| QUALITY: |
|
|
Michael Rose
Jenna Brashear
Omar Beirat
Jenna Brashear
Michael Rose
| Share Statistics | TECH | Industry Median |
Percentile (All Stocks) |
|
| Market Cap (Mil) | $11,224.3 | $1,774.7 | 79% |
|
| Shares Out (Mil) | 157.4 | 94.8 | 72% |
|
| Institutional Ownership | 99.7% | 90.1% | 93% |
|
| Float (Mil) | 155.2 | 69.9 | 70% |
|
| Beta | 1.40 | 1.20 | 79% |
|
| Avg Daily Volume (000s) | 4,105 | 838 | 91% |
|
| Price Change (52-week) |
24.5% | 81.0% | 65% |
|
| Growth | TECH | Industry Median |
Percentile (All Stocks) |
|
| Sales (5yr) | 10.5% | 7.8% | 60% |
|
| Net Income (5yr) | (20.4%) | (13.7%) | 19% |
|
| EPS (5yr) | (20.6%) | 0.7% | 13 |
|
| Dividends (5yr) | 0.0% | 0.0% | 64% |
|
| Cash Flow (5yr) | (25.3%) | (15.0%) | 25% |
|
| Estimates | Qtrly | Current Fiscal Year |
Next Fiscal Year |
|
| # of Estimates | 11 | 13 | 13 | |
| Current EPS | $0.519 | $1.918 | $2.044 | |
| Month Ago EPS | $0.519 | $1.919 | $2.045 | |
| # Rev Up | 0 | 0 | 0 | |
| # Rev Down | 1 | 0 | 1 | |
| Three Months Ago EPS | $0.564 | $1.977 | $2.162 | |
| Year/Year Chg | 62.2% | 317.0% | 400.4% | |
| Financials | TECH | Industry Median |
Percentile (All Stocks) |
|
| Sales (TTM) (Mil) | $1,211 | $763 | 53% |
|
| Net Income (TTM) (Mil) | $110 | ($14) | 62% |
|
| EPS (TTM) | $0.703 | ($0.200) | 57% |
|
| Operating Cash Flow (TTM) (Mil) | $295 | $53 | 64% |
|
| Net Cash Flow (TTM) (Mil) | $69 | ($5) | 74% |
|
| Long-Term Debt (Q1) (Mil) | $276 | $270 | 53% |
|
| Enterprise Value (Q1) (Mil) | $7,081 | $2,430 | 68% |
|
| Valuation | TECH | Industry Median |
Percentile (All Stocks) |
|
| P/B | 5.41 | 3.00 | 80% |
|
| P/E | 103.6 | 43.5 | 93% |
|
| Dividend Yield | 0.4% | 0.0% | 62% |
|
| PEG (5yr hist) | na | 5.3 | na |
|
| Ratios | TECH | Industry Median |
Percentile (All Stocks) |
|
| Gross Margin | 66.4% | 47.6% | 78% |
|
| Net Margin | 9.0% | (2.9%) | 60% |
|
| ROA | 4.2% | (3.2%) | 68% |
|
| ROE | 5.3% | (4.5%) | 45% |
|
| Liabilities to Assets | 18.2% | 43.0% | 11% |
|
| F-Score | 7 | 5 | 84% |
|
Bio-Techne Corporation did not pass any screens on 7/30/2026.
Price and market data provided by QuoteMedia and delayed a minimum of 15 minutes unless otherwise indicated. Fundamental data provided by AAII's Stock Investor Pro and S&P Global Market Intelligence and are updated through the previous trading day.
Ⓒ 2026 American Association of Individual Investors